# Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

> **NCT02679755** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 252 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02679755
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-07-25
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02679755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02679755, "Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02679755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*